Loading...
•
Sep 30, 2023
Rigel Q3 2023 Earnings Report
Rigel reported strong momentum from commercial hematology-oncology portfolio driven by record TAVALISSE net product sales and growing REZLIDHIA awareness among leukemia treaters.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $5.7 million on total revenues of $28.1 million for Q3 2023. Revenue was driven by TAVALISSE net product sales of $24.5 million and REZLIDHIA net product sales of $2.7 million.
Net loss was $5.7 million, or $0.03 per basic and diluted share, compared to a net loss of $19.0 million, or $0.11 per basic and diluted share, for the same period of 2022.
Total revenues were $28.1 million, including $24.5 million in TAVALISSE net product sales, $2.7 million in REZLIDHIA net product sales, and $1.0 million in contract revenues from collaborations.
TAVALISSE net product sales increased by $5.3 million, or 27%, compared to the same period of 2022.
Total costs and expenses were $32.6 million, compared to $40.8 million for the same period of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...